Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Ufuk Avrupa (Horizon Europe) · çağrı konusu HORIZON-MISS-2027-02-CANCER-03 (Supporting the implementation of the Cancer Mission). Başvurular 10 Şubat 2027 tarihinde açılır. Eylem türü: HORIZON Research and Innovation Actions.

Expected Outcome:

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:

• Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities;
• Researchers, physicians, innovators [1] , startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation; …

Kaynak: Avrupa Komisyonu Funding & Tenders Portal (otomatik aktarım; ayrıntı ve güncel koşullar için resmî sayfaya bakın).

"> General conditions

• Admissibility conditions: Proposal page limit and layout

described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

• Eligible countries

described in Annex B of the Work Programme General Annexes. …

Uygunluk: ülkenizin bu programa katılım durumunu ve ortaklık şartlarını resmî konu sayfasından teyit edin.